MUSCAT – Neuralink is considered one of the world’s leading pioneers in the field of Brain-Computer Interfaces (BCI), developing ultra-precise neural implants designed to be embedded in the brain to enable direct communication between humans and digital electronic devices, thereby unlocking new possibilities for treating complex neurological disorders.
Neuralink is among global companies developing technologies that enable direct communication between the brain and electronic devices, bypassing traditional sensory or motor pathways. These technologies are being utilized to support patients suffering from strokes or neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), which damages the motor neurons responsible for movement while cognitive abilities remain intact.
Neural devices, including brain implants, allow patients to translate brain signals into digital commands, such as typing or controlling devices. Recent clinical trial results demonstrated that the company’s first human patient was able to control a computer and type using thought alone, highlighting the transformative potential of this technology in restoring a degree of independence and improving quality of life.
The investment aligns with OIA’s efforts to diversify its international investment portfolio and strengthen its presence in innovative sectors and deep technology fields. Neuralink has received official approvals to conduct human clinical trials in the United States using highly precise robotic surgical technologies for implant procedures.
Over the past two years, the company has implanted its neural devices in 21 patients as of January 2026, including 17 procedures performed during 2025 alone, reflecting the accelerating pace of operations and expansion of clinical trials.
Neuralink is also working closely with regulatory authorities and participating hospitals to continuously improve its devices while maintaining the highest safety standards. To date, the company has recorded zero serious device-related adverse events, contributing to the rapid expansion of its clinical trial participant program, which grew from only three participants in 2024 to multiple participants per month during 2025.
In addition, the company is developing the “Blindsight” project, a neural visual prosthesis aimed at restoring vision by stimulating the brain’s visual cortex using digital camera inputs. The project’s name is inspired by a concept associated with visual perception in neuroscience, referring to the ability to respond to visual stimuli without full conscious awareness. Human trials for the technology are planned for the future, with early versions expected to provide low-resolution vision that will gradually improve as the technology advances.
Neuralink is distinguished by its vertically integrated operating model, managing all major stages of development in-house, including research and development, neural implant manufacturing, robotic surgery systems, neuroengineering, and specialized surgical teams. This integrated structure enables the company to accelerate technological development, enhance safety standards, and scale toward high-volume production in the coming years.
Notably, Oman Investment Authority’s investments are distributed across more than 52 countries worldwide, as part of its strategy to diversify its investment portfolio and strengthen its presence across sectors, contributing to financial sustainability and economic diversification goals.